Login to Your Account

Pharmamar inks deal with Chugai's European arm for MM drug Aplidin

By Shannon Ellis
Staff Writer

Wednesday, July 23, 2014

SHANGHAI – Pharmamar SA, of Madrid, has licensed the commercial rights to Aplidin (plitidepsin), an antitumour agent for multiple myeloma used in conjunction with dexamethasone, to Chugai Pharmaceutical Marketing Ltd., the European arm of Japanese parent company Chugai Pharmaceutical.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription